Insider Selling: XOMA Co. (NASDAQ:XOMA) Major Shareholder Sells 500,742 Shares of Stock

XOMA Co. (NASDAQ:XOMA) major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

XOMA Stock Down 2.9 %

NASDAQ XOMA traded down $0.78 during trading on Tuesday, reaching $26.48. The company’s stock had a trading volume of 11,377 shares, compared to its average volume of 69,228. The business has a 50-day moving average price of $28.13 and a 200-day moving average price of $28.12. XOMA Co. has a 1-year low of $19.50 and a 1-year high of $35.00. The stock has a market capitalization of $311.93 million, a PE ratio of -7.61 and a beta of 0.92. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28.

XOMA (NASDAQ:XOMA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.05. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The firm had revenue of $7.20 million for the quarter, compared to the consensus estimate of $6.66 million. On average, research analysts forecast that XOMA Co. will post -1.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $123.00 price objective on shares of XOMA in a research note on Tuesday, January 7th. StockNews.com raised shares of XOMA from a “sell” rating to a “hold” rating in a research report on Thursday, January 16th.

Institutional Investors Weigh In On XOMA

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets lifted its position in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares during the last quarter. Barclays PLC boosted its position in shares of XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after acquiring an additional 8,447 shares during the period. Ellsworth Advisors LLC acquired a new stake in shares of XOMA in the third quarter worth $516,000. State Street Corp increased its position in XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after acquiring an additional 1,754 shares during the period. Finally, Geode Capital Management LLC increased its position in XOMA by 0.6% during the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after acquiring an additional 1,138 shares during the period. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.